VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
QGENQiagen N.V.
$39.41$8.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksQGENFinancials

Qiagen N.V. (QGEN) Financials

30Y historyFree accessUpdated daily

Revenue growth has slowed to 1.8% in 2026Q1, while operating margins remain under pressure at 23.7% due to persistent SG&A overhead.

QGEN Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Sales/Revenue2.1B2.09B1.98B1.97B2.14B2.25B1.87B1.53B1.5B1.42B1.34B1.28B1.34B1.3B1.25B1.17B1.09B1.01B892.98M649.77M465.78M398.39M380.63M351.4M298.61M263.77M204.03M143.96M110.2M74.3M54.2M
Revenue Growth %4.79%5.65%0.66%-8.23%-4.89%20.39%22.53%1.64%5.95%5.95%4.45%-4.74%3.29%3.79%7.24%7.57%7.69%13.09%37.43%39.5%16.91%4.67%8.32%17.68%13.21%29.28%41.73%30.64%48.32%37.08%46.49%
Cost of Goods Sold806.45M798.5M1.01B731.62M756.96M800.84M637.63M521.16M500.89M494.98M493.34M454.33M479.57M486.49M430.43M419.94M371.87M342.75M293.29M216.23M141.17M123.19M127.11M122.4M96.51M79.67M65.44M37.27M31.88M15.1M12.2M
COGS % of Revenue-38.21%51.1%37.23%35.35%35.57%34.09%34.14%33.35%34.92%36.87%35.47%35.66%37.37%34.31%35.9%34.2%33.94%32.84%33.28%30.31%30.92%33.4%34.83%32.32%30.21%32.07%25.89%28.92%20.32%22.51%
Gross Profit1.29B1.29B967.35M1.23B1.38B1.45B1.23B1.01B1B922.56M844.65M826.66M865.21M815.49M824.02M749.81M715.56M667.07M599.69M433.55M324.61M275.2M253.52M229M202.1M184.1M151.37M120.88M88.93M59.17M42M
Gross Margin %61.58%61.79%48.9%62.77%64.65%64.43%65.91%65.86%66.65%65.08%63.13%64.53%64.34%62.63%65.69%64.1%65.8%66.06%67.16%66.72%69.69%69.08%66.6%65.17%67.68%69.79%74.19%83.97%80.7%79.64%77.49%
Gross Profit Growth %-33.51%-21.59%-10.9%-4.57%17.69%22.63%0.43%8.5%9.22%2.18%-4.46%6.1%-1.04%9.9%4.79%7.27%11.24%38.32%33.56%17.95%8.55%10.71%13.31%9.78%21.62%25.22%35.93%50.28%40.89%43.34%
Operating Expenses770.83M771.18M869.64M823.75M853.1M820.74M846.28M1.03B734.38M769.14M745.83M647.16M703.51M752.16M654.21M650.22M527.02M486.87M454.03M350.41M224.01M180.36M169.38M160.11M158.91M130.62M114.83M97.53M73.01M50.9M36M
OpEx % of Revenue-36.9%43.96%41.91%39.84%36.45%45.25%67.57%48.9%54.26%55.74%50.52%52.31%57.77%52.15%55.59%48.47%48.21%50.84%53.93%48.09%45.27%44.5%45.56%53.22%49.52%56.28%67.75%66.25%68.51%66.42%
Selling, General & Admin588.12M583.67M564.36M579.17M603.95M584.47M525.36M504.17M533.5M575.66M530.6M464.84M503.42M570.6M495.62M492.84M377.49M360.75M341.34M236.62M164.52M134.81M129.22M125.27M117.12M100.85M82.17M61.26M50M37.7M27M
SG&A % of Revenue-27.93%28.53%29.47%28.2%25.96%28.09%33.03%35.52%40.61%39.66%36.29%37.44%43.82%39.51%42.13%34.71%35.72%38.23%36.42%35.32%33.84%33.95%35.65%39.22%38.23%40.27%42.55%45.37%50.74%49.82%
Research & Development191.99M187.52M193.49M198.51M189.86M189.96M149.07M157.45M161.85M154.08M176.13M147.18M163.63M146.07M122.48M130.64M126.04M107.9M97.33M64.94M41.56M39.1M34.16M31.79M28.18M26.77M22.21M16.27M12.8M8.3M6.5M
R&D % of Revenue-8.97%9.78%10.1%8.87%8.44%7.97%10.31%10.78%10.87%13.16%11.49%12.17%11.22%9.76%11.17%11.59%10.69%10.9%9.99%8.92%9.81%8.97%9.05%9.44%10.15%10.89%11.3%11.62%11.17%11.99%
Other Operating Expenses2M0111.78M46.07M59.3M46.3M171.85M369.78M75.68M137.42M39.09M38.67M37.07M35.49M36.12M26.75M23.49M18.22M15.35M48.86M17.93M6.45M6M3.05M13.62M3M5.35M13.66M6.27M4.9M2.5M
Operating Income521.59M520.31M97.71M409.94M531.46M630.08M386.43M-26.14M266.58M153.42M98.83M179.5M161.69M63.33M169.81M99.59M188.54M180.21M145.66M83.13M100.6M94.84M84.14M68.89M43.19M53.48M36.53M23.35M15.92M8.27M6M
Operating Margin %24.85%24.9%4.94%20.86%24.82%27.98%20.66%-1.71%17.75%10.82%7.39%14.01%12.02%4.86%13.54%8.51%17.34%17.85%16.31%12.79%21.6%23.8%22.11%19.6%14.46%20.27%17.91%16.22%14.44%11.14%11.07%
Operating Income Growth %-432.5%-76.16%-22.87%-15.65%63.05%1578.54%-109.8%73.76%55.24%-44.94%11.01%155.32%-62.71%70.52%-47.18%4.62%23.71%75.22%-17.36%6.08%12.71%22.14%59.52%-19.24%46.38%56.47%46.68%92.39%37.9%27.66%
EBITDA805.96M714.06M300.98M615.27M739.86M845.01M591.45M205.32M473.02M369.87M311.88M370.97M198.76M98.83M205.93M126.33M212.03M300.6M251.37M145.72M130.64M119.79M107.1M94.68M67.89M68.53M46.99M31.18M21.72M13.17M8.5M
EBITDA Margin %38.4%34.17%15.21%31.31%34.55%37.53%31.62%13.45%31.5%26.09%23.31%28.96%14.78%7.59%16.42%10.8%19.5%29.77%28.15%22.43%28.05%30.07%28.14%26.94%22.74%25.98%23.03%21.66%19.71%17.73%15.68%
EBITDA Growth %159.19%137.24%-51.08%-16.84%-12.44%42.87%188.06%-56.59%27.89%18.59%-15.93%86.64%101.13%-52.01%63.01%-40.42%-29.46%19.59%72.5%11.54%9.05%11.85%13.12%39.45%-0.94%45.86%50.7%43.56%64.85%54.99%30.77%
D&A (Non-Cash Add-back)284.38M193.75M203.27M205.34M208.4M214.93M205.01M231.46M206.44M216.45M213.06M191.47M37.07M35.49M36.12M26.75M23.49M120.39M105.7M62.58M30.04M24.95M22.96M25.79M24.71M15.06M10.46M7.83M5.8M4.9M2.5M
EBIT493.56M523.52M164.99M483.22M570.96M680.31M510.79M-3.59M293.03M164.06M95.93M173.7M158.72M68.22M168.6M121.57M200.94M201.97M156.81M131.99M110.31M101.29M88.53M71.94M56.81M53.48M36.53M37.01M22.18M8.27M6M
Net Interest Income22.48M31.06M24.18M25.58M-25.6M-44.92M-61.28M-52.07M-46.44M-39.04M-32.25M-32.64M-35.37M-28.58M-21.07M-19.23M-23.36M-26.12M-28.02M000000000000
Interest Income59.49M64.32M68.02M78.99M32.76M9.55M10.03M22.11M20.85M10.64M6.78M4.75M3.96M2.3M2.38M6.13M4.46M3.52M9.51M000000000000
Interest Expense37.01M33.26M43.84M53.41M58.36M54.48M71.32M74.19M67.29M49.69M39.02M37.4M39.33M30.88M23.45M25.36M27.82M29.64M37.53M000000000000
Other Income/Expense-65.04M-30.04M23.44M19.87M-18.86M-4.25M53.04M-51.64M-40.84M-39.04M-41.92M-43.2M-42.3M-25.99M-24.66M-3.38M-15.42M-7.88M-26.38M-7.41M5.47M2.43M-11.45M-1.63M-4.32M2.84M2.59M1.49M2.74M5.33M2.6M
Pretax Income456.55M490.26M121.15M429.81M512.6M625.83M439.47M-77.78M225.74M114.38M56.91M136.3M119.39M37.34M145.15M96.21M173.12M172.33M119.29M75.73M106.07M97.26M72.69M67.25M38.87M56.31M39.12M24.84M18.66M13.6M8.6M
Pretax Margin %21.75%23.46%6.12%21.87%23.94%27.79%23.5%-5.1%15.03%8.07%4.25%10.64%8.88%2.87%11.57%8.22%15.92%17.07%13.36%11.65%22.77%24.41%19.1%19.14%13.02%21.35%19.18%17.25%16.93%18.3%15.87%
Income Tax54.38M65.39M37.56M88.51M89.39M113.23M80.28M-36.32M35.36M73.98M-23.39M6.4M2.46M-31.76M15.62M1.26M28.81M34.56M29.76M25.55M35.53M35.04M23.98M24.41M15.72M21.9M18.09M10.95M5.49M4.8M3.3M
Effective Tax Rate %11.91%13.34%31%20.59%17.44%18.09%18.27%46.7%15.66%64.68%-41.11%4.7%2.06%-85.06%10.76%1.31%16.64%20.06%24.95%33.75%33.5%36.02%32.99%36.29%40.46%38.88%46.22%44.08%29.42%35.29%38.37%
Net Income402.17M424.88M83.59M341.3M423.21M512.6M359.19M-41.45M190.38M40.39M80.4M130.15M116.36M69.07M129.51M96.04M144.31M137.77M89.03M50.12M70.54M62.23M48.7M42.85M23.14M34.42M21M13.89M13.17M8.8M5.3M
Net Margin %19.16%20.33%4.23%17.37%19.76%22.77%19.2%-2.72%12.68%2.85%6.01%10.16%8.65%5.31%10.32%8.21%13.27%13.64%9.97%7.71%15.14%15.62%12.8%12.19%7.75%13.05%10.29%9.65%11.95%11.84%9.78%
Net Income Growth %329.31%408.28%-75.51%-19.35%-17.44%42.71%966.45%-121.77%371.31%-49.76%-38.22%11.84%68.47%-46.66%34.85%-33.45%4.75%54.74%77.63%-28.94%13.36%27.76%13.66%85.16%-32.76%63.88%51.22%5.49%49.61%66.04%120.83%
Net Income (Continuing)402.17M424.88M83.59M341.3M423.21M512.6M359.19M-41.45M190.38M40.39M80.3M126.86M116.93M69.1M129.54M94.95M144.31M137.77M89.52M50.17M70.54M62.23M48.7M42.85M23.14M34.42M21M13.89M13.17M8.8M5.3M
Discontinued Operations0000000000000000000000000000000
Minority Interest000000000002.03M8.26M9.54M9.66M9.49M000553K000000193K269K100K00
EPS (Diluted)1.922.040.381.652.052.470.32-0.190.820.170.350.560.500.300.560.420.620.660.460.290.480.430.340.300.170.250.150.100.090.070.05
EPS Growth %339.53%436.84%-76.97%-19.51%-17%671.88%268.42%-123.17%382.35%-51.43%-37.5%12%66.67%-46.43%33.33%-32.26%-6.06%43.48%58.62%-39.58%11.63%26.47%13.33%76.47%-32%66.67%50%6.95%28.61%40.08%66.35%
EPS (Basic)-2.040.391.672.082.520.33-0.190.840.180.360.570.520.310.570.430.640.700.470.310.490.440.340.300.170.250.160.100.090.070.05
Diluted Shares Outstanding208.94M207.94M218.47M217.49M223.23M225.07M227.19M219.97M233.46M233.01M230.14M228.37M232.59M233.21M231.83M230.21M231.58M205.7M196.69M169.44M147.83M144.61M143.02M141.72M140.39M139.68M139.7M133.75M140.87M121.06M102.07M
Basic Shares Outstanding207.01M207.94M216.44M217.49M220.75M221.14M221.57M219.97M225.51M228.07M225.87M224.38M223.43M225.23M225.86M225.55M224.48M199.26M189.51M162.22M143.97M142.36M141.23M140.43M139.43M137.67M136.78M133.75M140.87M121.06M102.07M
Dividend Payout Ratio-12.77%-----------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityModerate
Balance SheetHealthy
Cash FlowStable
Top Statement Risk

Diagnostic market share erosion

Revenue Growth Faces Normalization Headwinds

According to recent financial filings, QGEN's revenue growth has decelerated to 1.8% in 2026Q1, reflecting a challenging transition as the company moves past pandemic-era testing volumes and navigates a more cautious academic research funding environment that continues to weigh on its top-line performance.

The current revenue trajectory suggests that the company is struggling to find a new growth baseline following the volatility of the COVID-19 period. Investors should monitor whether the 'Five Pillars' strategy can sufficiently offset the decline in legacy testing volumes to return the company to sustainable mid-single-digit growth.

Structural Margin Resilience Amid Volatility

As reported in quarterly statements, QGEN maintained a gross margin of 62.9% in 2026Q1, demonstrating the inherent pricing power of its proprietary sample preparation consumables despite the significant margin compression observed during the anomalous 2024Q2 period due to one-time operational charges.

The stability of gross margins near the 62% level indicates that the company's 'razor-blade' business model remains intact. However, the sensitivity of operating margins to product mix shifts suggests that management must maintain strict discipline in its R&D and SG&A spending to protect bottom-line profitability.

Operating Leverage Remains Under Pressure

Based on the provided income statement data, QGEN's operating margin of 23.7% in 2026Q1 highlights a lack of significant operating leverage, as SG&A expenses continue to consume a substantial portion of gross profit, limiting the scalability of the company's current diagnostic and research platform.

The inability to consistently expand operating margins despite stable gross margins suggests that the company's cost structure is heavily weighted toward fixed overheads. This warrants further investigation into whether the current investment in the 'Five Pillars' will eventually yield the expected efficiency gains or if structural costs will remain a persistent drag.

Earnings Quality Impacted by Volatility

Data from recent filings indicates that QGEN's net income has experienced significant fluctuations, with EPS falling to 0.33 in 2026Q1, a decline of 19.5% year-over-year, which appears to be driven by both top-line stagnation and the ongoing impact of non-operating items on the bottom line.

The variability in net income suggests that investors should look beyond headline EPS to understand the underlying cash-generating capability of the business. The consistent presence of stock-based compensation and potential integration costs from acquisitions necessitates a cautious approach when evaluating the sustainability of current earnings levels.

Competitive Risks to Core Moat

As highlighted in the provided financial data, the 2026Q1 revenue growth of 1.8% may indicate that QGEN's competitive moat in sample preparation is being tested by emerging automated T-cell assays and increased competition in the latent TB market, which could threaten its primary diagnostic growth driver.

Short-sellers would likely focus on the potential for margin compression if the company is forced to lower prices to defend its market share against more agile, automated competitors. The reliance on a few key diagnostic pillars makes the company vulnerable to any successful disruption in its core clinical workflows.

QGEN — Frequently Asked Questions

Quick answers to the most common questions about buying QGEN stock.

What was Qiagen N.V.'s (QGEN) revenue in 2025?

For fiscal year 2025, Qiagen N.V. (QGEN) reported total revenue of $2.09B. This represents a 3756.1% increase compared to $54.2M in 1996.

Is Qiagen N.V. (QGEN) profitable?

Qiagen N.V. (QGEN) is profitable, generating $424.9M in net income for the fiscal year ending 2025 with a net profit margin of 20.3%.

What is Qiagen N.V.'s operating profit margin?

Qiagen N.V. (QGEN) reported an operating income of $520.3M, resulting in an operating profit margin of 24.9%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Qiagen N.V.'s gross profit and gross margin?

Qiagen N.V. (QGEN) generated $1.29B in gross profit for the year, representing a gross profit margin of 61.8%. This demonstrates the company's core pricing power and production efficiency.